Gennaro Pagano, MD, MSc, PhD, Expert Medical Director, Group Leader, Chair of Medical Directors Fellows at Roche Pharma Research and Early Development (pRED) and Researcher at King’s College London, shares his thoughts on the current exciting updates in the Parkinson’s disease field and what is to come in the next few years. Dr Genaro highlights the promising results of prasinezumab on disease progression and the better understanding and continued research on disease biology. This interview took place during the AD/PD™ 2021 conference.